

Coordinator contact details

Project Coordinator

- Josep Ferrés Corominas, Corporate Quality Compliance Executive Director at HIPRA (josep.ferres@hipra.com).

List of participants

- **Project Coordinator:** Josep Ferrés.
- **Technical Coordinator:** Laura Ferrer.
- **Project Manager:** Marc Biarnés.
- **Financial QA Manager:** Patricia Soler.
- **Technical QA Manager and Scientific Writer:** Neus Cantariño.

| | |
|--|---|
| <p>WP1: Project Management and Coordination</p> <p>WP1 will ensure the correct implementation of the project, maintaining alignment with its scientific, technological, and strategic goals.</p> | <p>Leads: Laura Ferrer and Marc Biarnés Collaborators: Josep Ferrés and Neus Cantariño.</p> |
| <p>WP2: Development of a gene synthesis platform</p> <p>WP2 will develop a fully integrated in-house gene synthesis platform that drastically shortens the development timelines for biological products.</p> | <p>Lead: Berta Marcó. Collaborator: Núria Casas.</p> |
| <p>WP3: CHO expression platform development focused on speed.</p> <p>WP3 will develop a fully integrated in-house gene synthesis platform that drastically WP3 aims to accelerate and streamline biopharmaceutical development by introducing novel and efficient strategies for plasmid engineering. Shortening the development timelines for biological products.</p> | <p>Lead: Álex Fernández. Collaborator: Laura Salse.</p> |



| | |
|--|--|
| <p>WP4: Cell line and process development streamlining</p> <p>WP4 will focus on optimizing and accelerating Cell Line Development (CLD) workflows through advanced technologies and integrated processes. To further streamline operations, Upstream Process (USP) development activities are embedded directly within the CLD workflow and conducted in parallel with seed lot system preparation.</p> | <p>Lead: Laura Salse. Collaborator: Àlex Fernández.</p> |
| <p>WP5: Speedy cGMP-compliant and representative active substance from stable pools, and design of emergency preclinical programs</p> <p>WP5 aims to drastically reduce development timelines by establishing strategies for producing representative active substances from stable pools within a targeted timeframe of under 30 days from sequence to purified active substances. To support rapid response capabilities, an accelerated preclinical framework will be established as a reference model for health emergencies.</p> | <p>Lead: Toni Prenafeta. Collaborator: Ricard March.</p> |
| <p>WP6: Platform assembly and Pilot trials</p> <p>WP6 involves assembling a comprehensive and modular CLD platform that integrates all critical stages. The platform's operational readiness will be rigorously tested through pilot trials simulating emergency conditions.</p> | <p>Lead: Clara Panosa. Collaborator: Iván Martínez.</p> |
| <p>WP7: Regulatory compliance</p> <p>WP7 will ensure that all newly developed technologies and processes are fully compliant with current regulatory standards, enabling their immediate application in real-world scenarios and securing endorsement from leading regulatory bodies.</p> | <p>Lead: David Pérez. Collaborator: Laura Cufí.</p> |
| <p>WP8: Business, Sustainability and Intellectual Property Rights (IPR)</p> <p>WP8 will ensure the long-term exploitation and impact of SPEEDCELL's results through the development of a comprehensive business plan.</p> | <p>Lead: Eduard Viladesau. Collaborator: Glòria Pujol.</p> |



WP9: Communication & Dissemination

WP9 will communicate the state and results of the SPEEDCELL project. It will also participate in major European and international events and conferences to increase visibility and awareness of the present project, and will establish contact and collaborate with related EU initiatives and agencies related with the approval of the manufacturing process.

Lead: Marc Marqués.

Collaborator: Neus Cantariño.

More information about the SPEEDCELL project: www.speedcellproject.eu

Press contact: HIPRA Press: press@hipra.com | T (+34) 972 43 06 60

